As of 2025-10-20, the EV/EBITDA ratio of Myriad Genetics Inc (MYGN) is -41.74. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MYGN's latest enterprise value is 784.71 mil USD. MYGN's TTM EBITDA according to its financial statements is -18.80 mil USD. Dividing these 2 quantities gives us the above MYGN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.6x - 16.1x | 14.6x |
| Forward P/E multiples | 12.5x - 15.0x | 13.7x |
| Fair Price | (3.15) - (3.67) | (3.50) |
| Upside | -140.4% - -147.0% | -144.9% |
| Date | EV/EBITDA |
| 2025-10-17 | -41.74 |
| 2025-10-16 | -43.13 |
| 2025-10-15 | -43.22 |
| 2025-10-14 | -41.74 |
| 2025-10-13 | -41.94 |
| 2025-10-10 | -40.26 |
| 2025-10-09 | -41.44 |
| 2025-10-08 | -40.95 |
| 2025-10-07 | -40.40 |
| 2025-10-06 | -42.68 |
| 2025-10-03 | -43.03 |
| 2025-10-02 | -40.55 |
| 2025-10-01 | -41.39 |
| 2025-09-30 | -38.92 |
| 2025-09-29 | -38.94 |
| 2025-09-26 | -41.25 |
| 2025-09-25 | -41.54 |
| 2025-09-24 | -41.34 |
| 2025-09-23 | -41.25 |
| 2025-09-22 | -41.94 |
| 2025-09-19 | -41.59 |
| 2025-09-18 | -41.15 |
| 2025-09-17 | -39.76 |
| 2025-09-16 | -40.26 |
| 2025-09-15 | -39.32 |
| 2025-09-12 | -38.97 |
| 2025-09-11 | -41.15 |
| 2025-09-10 | -37.29 |
| 2025-09-09 | -37.63 |
| 2025-09-08 | -37.34 |
| 2025-09-05 | -35.85 |
| 2025-09-04 | -36.74 |
| 2025-09-03 | -36.79 |
| 2025-09-02 | -37.29 |
| 2025-08-29 | -34.66 |
| 2025-08-28 | -33.92 |
| 2025-08-27 | -32.49 |
| 2025-08-26 | -31.89 |
| 2025-08-25 | -32.29 |
| 2025-08-22 | -32.93 |
| 2025-08-21 | -31.99 |
| 2025-08-20 | -30.51 |
| 2025-08-19 | -30.41 |
| 2025-08-18 | -31.40 |
| 2025-08-15 | -31.40 |
| 2025-08-14 | -32.29 |
| 2025-08-13 | -32.19 |
| 2025-08-12 | -32.98 |
| 2025-08-11 | -33.77 |
| 2025-08-08 | -34.42 |